Cov txiaj ntsig ntawm SS-31 peptide yog dab tsi?
SS-31 peptide hmoov(Elamipretide) yog ib qho hluavtaws me me-molecule peptide uas nws lub luag haujlwm tseem ceeb yog txhawm rau tsom thiab kho lub cell "lub zog hluav taws xob"- lub mitochondria. Los ntawm kev xaiv khi rau cardiolipin nyob rau hauv lub puab mitochondrial membrane, nws stabilizes mitochondrial qauv, txo cov to ntawm teeb meem dawb radicals, thiab txhim khu kev ua hauj lwm ntawm cellular zog (ATP) ntau lawm. Kev tshawb fawb tam sim no qhia tau hais tias nws tuav cov lus cog tseg rau kev txhim kho lub plawv muaj nuj nqi, ncua cov leeg nqaij qaug zog, thiab muab cov neuro- thiab kev tiv thaiv retinal; nws qhov kev ua tau zoo yog qhov tseem ceeb tshwj xeeb hauv cov qauv ntawm mitochondrial-txog kab mob thiab hnub nyoog- cuam tshuam txog cov kab mob metabolic.
Lub ntsiab lus luv luv ntawm Mechanism of Action ntawm SS-31 Peptide
SS-31 peptide xaiv khi rau cardiolipin nyob rau hauv mitochondrial puab daim nyias nyias, yog li stabilizing mitochondrial qauv thiab txo cov to ntawm reactive oxygen hom (ROS) los ntawm cov electron thauj saw, thaum kawg pab txhawb zog metabolic efficiency. Cias muab, nws ua raws li "tus kws kho mob mitochondrial," txo kev puas tsuaj cuam tshuam nrog cellular aging.
Cov txiaj ntsim kev noj qab haus huv tseem ceeb
1. Txhim kho plawv muaj nuj nqi
Ntau qhov kev tshawb fawb hauv tsev kho mob tau pom tias SS-31 tuaj yeem txo qhov kev raug mob ntawm myocardial ischemia-reperfusion, ua rau lub plawv ejection feem ntau, thiab ua rau muaj kev tiv thaiv tshwj xeeb hauv tsiaj cov qauv ntawm lub plawv tsis ua haujlwm.
2. Kev txo qis ntawm pob txha pob txha thiab kev ua haujlwm tsis zoo ntawm kev ua haujlwm siab
Hauv cov tsiaj muaj hnub nyoog thiab cov qauv ntawm mitochondrial myopathy, SS-31 txo cov leeg pob txha ntawm tes apoptosis thiab txhim kho ATP synthesis, yog li ncua cov leeg nqaij qaug zog thiab txhim kho kev tawm dag zog.
3. Cov nyhuv Neuroprotective
Hauv cov ntsiab lus ntawm cov kab mob neurodegenerative xws li Parkinson's disease thiab Alzheimer's disease, SS-31 tau pom tias yuav txo qis intracellular oxidative kev nyuaj siab hauv cov paj hlwb, txhim kho synaptic plasticity, thiab inhibit toxicity cuam tshuam nrog cov protein sib xyaw ua ke.
4. Kev tiv thaiv lub raum thiab Retina
Lub raum: Hauv cov qauv ntawm mob raum raug mob thiab mob ntshav qab zib nephropathy, SS-31 txo qhov mob podocyte thiab tubulointerstitial fibrosis.
Retina: Cov qauv ntawm lub hnub nyoog- ntsig txog macular degeneration thiab Leber's hereditary optic neuropathy tau pom tias SS-31 tuaj yeem tiv thaiv cov duab receptors thiab cov hlwb hauv lub hlwb.
5. Kev Txom Nyem Ntawm Kev Laus -Txog Metabolic Disorders
SS-31 txhim kho insulin rhiab heev rau cov nas muaj hnub nyoog, txo qhov mob hauv cov ntaub so ntswg adipose, thiab-hauv qee qhov kev tshawb fawb-pom qhov sib piv rau kev ncua kev noj qab haus huv.
Qhov tseem ceeb ntawm kev sim tshuaj ntsuam xyuas (Raws li ntawm 2025)
| Qhov taw qhia | Phase kho mob | Cov ntsiab lus tseem ceeb | Summary of Results |
|---|---|---|---|
| Primary Mitochondrial Disease | Phase II/III | 6-feeb taug kev deb, nkees nkees | Kev txhim kho tau pom nyob rau hauv qee pawg sub; tsis tau raws li cov ntsiab lus tseem ceeb |
| Heart Failure with Preserved Ejection Fraction (HFpEF) | Phase II | Sab laug ventricular filling siab, ua haujlwm siab ntev | Pom zoo cov cim; xav kom loj dua -scale validation |
| Duchenne Muscular Dystrophy- txuam nrog Cardiomyopathy | Phase II | Sab laug ventricular strain thiab myocardial fibrosis markers | Cov txiaj ntsig ua ntej qhia txog kev nyab xeeb thiab kev txhim kho kev ua haujlwm |
Khoom Description
Piv nrog rau cov tshuaj antioxidants ib txwm muaj xws li Coenzyme Q10 thiab Vitamin C, SS-31 peptide muaj cov txheej txheem sib txawv ntawm kev ua thiab ntau qhov txiaj ntsig zoo. Cov lus hauv qab no qhia txog qhov sib txawv tseem ceeb no.
| Feature | Cov tshuaj Antioxidants (piv txwv li, CoQ10, Vitamin C) | SS-31 Peptide hmoov |
|---|---|---|
| Mechanism / Lub Hom Phiaj | Tsis yog - tshwj xeeb dawb radical scavenging | Kev khi tshwj xeeb rau cardiolipin; site- tshwj xeeb inhibition ntawm oxidation |
| Mitochondrial Accumulation Capacity | Tsawg | High (zoo them, enriched nyob rau hauv lub puab membrane) |
| Kho ntawm Mitochondrial Cristae Structure | Tsis muaj | Yog lawm |
| Qhov cuam tshuam rau Electron Transport Chain | Tsis ncaj | Kev tiv thaiv ncaj qha ntawm Complex I thiab IV kev ua haujlwm |
Kev nyab xeeb thiab kev txwv
- Kev Phem Tsis Zoo: Hauv Phase I thiab Phase II kev sim, cov xwm txheej tsis zoo tshwm sim feem ntau yog me me mus rau nruab nrab txhaj tshuaj- qhov tshwm sim ntawm qhov chaw (liab, o, thiab mob); tsis muaj tshuaj hnyav heev -txog hepatotoxicity lossis cardiotoxicity tau pom.
- Kev txwv: Oral bioavailability is extremely low, and all currently available formulations are administered via subcutaneous or intravenous injection; long-term (>6 lub hlis) cov ntaub ntawv kev nyab xeeb tseem txwv; thiab qee qhov chaw kho mob kawg ua tsis tiav los ua kom pom qhov sib txawv tseem ceeb.
Kev nthuav dav ntawm kev tshawb fawb thiab kev siv
Tshaj li cov cheeb tsam tseem ceeb tau hais los saum no-xws li mob plawv, paj hlwb, thiab lub raum mob -Kev tshawb fawb tshiab tau nthuav dav qhov kev siv ntawm SS-31 daim ntawv thov mus rau ib qho ntawm cov kab mob uas tsis xav tau ntau dua.
| Emerging Field | Daim ntawv qhia kev | Mechanism / Kev Tshawb Fawb Highlight |
|---|---|---|
| Daim tawv nqaij & Photoaging | UV-induced tawv nqaij puas | Encapsulating SS-31 hauv cov kua mis exosomes los ua Exo-SS31 complex zoo tiv thaiv collagen degradation, nrog cov teebmeem zoo dua rau SS-31 ib leeg. |
| Pob txha & Kab Mob Sib Kis | Osteoporosis, osteoarthritis, mob ntshav qab zib pob txha | Los ntawm kev tshem tawm mitochondrial reactive oxygen hom (ROS) thiab txhim kho mitochondrial muaj nuj nqi, SS-31 tau qhia txog kev kho mob hauv cov qauv ntawm cov pob txha thiab pob txha. |
| Cov Kab Mob Qhov Muag | Hnub nyoog -txog macular degeneration (AMD), Leber hereditary optic neuropathy (LHON) | Lub hom phiaj thiab tiv thaiv mitochondria hauv cov hlwb retinal; cov kev sim tshuaj cuam tshuam tseem tab tom ua tam sim no. |
| Drug Delivery Systems | Tsim kom meej ntau "missiles" | SS-31 feem ntau yog siv los ua "kev taw qhia lub taub hau," sib txuas nrog lwm cov tshuaj (xws li cov tshuaj tiv thaiv -cov tshuaj tiv thaiv kev laus rapamycin) los tsim cov tshuaj tiv thaiv ntau yam uas ua rau cov mitochondria. |
Ib lub hom phiaj tseem ceeb los qhia rau cov nyeem yog qhov ntawd, thaum daim ntawv thov ntawm SS-31 hauv kev kho qhov muag kab mob tau txais kev cia siab heev, cov txiaj ntsig ua ntej los ntawm Phase 2 kev sim tshuaj rau hnub nyoog- ntsig txog macular degeneration qhia tias nws ua tsis tau raws li cov ntsiab lus tseem ceeb ntawm kev ua tau zoo; cov kev tshawb fawb tom qab tseem tab tom ua tam sim no. Qhov no yog ib qho piv txwv tseem ceeb ntawm feem ntau winding thiab unpredictable xwm ntawm scientific nug.
Cov ntsiab lus tshawb fawb
SS-31 peptide sawv cev rau cov tswv yim kho tshiab uas nyob rau ntawm "stabilization ntawm mitochondrial inner membrane."Thaum nws tus nqi preclinical thoob plaws plawv, paj hlwb, nqaij, thiab metabolic domains tau zoo-tsim,nyob rau theem tam sim no, nws yog ib qho tseem ceeb kom ua tib zoo paub qhov txawv ntawm "cov pov thawj scientific" thiab "cov khoom paub tab."
